Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency - 17/08/11
⁎ 
Reprint requests: Marcel Levi, MD, Department of Medicine (F-4), Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, The Netherlands.Amsterdam, The Netherlands
Abstract |
Background |
Administration of C1-inhibitor concentrate is effective for prophylaxis and treatment of severe angioedema attacks caused by C1-inhibitor deficiency. The concentrate should be administered intravenously and hence needs to be administered by health care professionals, which might cause considerable delay in treatment and inconvenience for patients.
Objective |
The aim of this study was to investigate the feasibility, efficacy, and safety of on-demand and prophylactic self-administration of C1-inhibitor concentrate in patients with frequent attacks of angioedema.
Methods |
Patients with hereditary or acquired C1-inhibitor deficiency who had very frequent angioedema attacks were trained to self-administer C1-inhibitor concentrate. The study consisted of 31 patients using on-demand treatment and 12 patients using prophylaxis with C1-inhibitor concentrate. Mean follow-up was 3.5 years.
Results |
All patients were capable of self-administering the concentrate, with technical failure rates of self-injection being less than 2%. Times between the onset of the attack and the initiation of relief or complete resolution of symptoms in the on-demand group were significantly shortened (2.2 hours and 7.9 hours, respectively) compared with the situation before the start of self-administration. In the prophylaxis group self-administration of C1-inhibitor concentrate decreased the angioedema attack rate from 4.0 to 0.3 attacks per month.
Conclusion |
Intravenous self-administration of C1-inhibitor concentrate is a feasible and safe option and results in more rapid and more effective treatment or prevention of severe angioedema attacks in patients with C1-inhibitor deficiency.
Clinical implications |
Self-administration of C1-inhibitor concentrate could be a valuable and convenient treatment modality to prevent or treat angioedema attacks in patients with C1-inhibitor deficiency.
Le texte complet de cet article est disponible en PDF.Key words : C1-inhibitor deficiency, C1-inhibitor concentrate, hereditary angioedema, acquired angioedema
Plan
| Disclosure of potential conflict of interest: The authors have declared they have no conflict of interest. |
Vol 117 - N° 4
P. 904-908 - avril 2006 Retour au numéro
Article précédent
- Mutations in the RNA component of RNase mitochondrial RNA processing might cause Omenn syndrome
- Chaim M. Roifman, Yiping Gu, Amos Cohen
- Association of CD4+ T-lymphocyte counts and new thymic emigrants in HIV-infected children during successful highly active antiretroviral therapy
- Akihiko Saitoh, Kumud K. Singh, Sharsti Sandall, Christine A. Powell, Terrence Fenton, Courtney V. Fletcher, Karen Hsia, Stephen A. Spector
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?